Free Trial

Alvotech (ALVO) Competitors

Alvotech logo
$8.81 -0.21 (-2.33%)
As of 04:00 PM Eastern

ALVO vs. QGEN, VTRS, ASND, MRNA, BBIO, BPMC, VRNA, ROIV, ELAN, and RVMD

Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

Alvotech vs. Its Competitors

Alvotech (NASDAQ:ALVO) and Qiagen (NYSE:QGEN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Qiagen has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$491.98M5.40-$231.86M$0.3723.81
Qiagen$1.98B5.38$83.59M$0.40119.60

Alvotech has a net margin of 16.42% compared to Qiagen's net margin of 4.68%. Qiagen's return on equity of 14.61% beat Alvotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Alvotech16.42% -36.37% 12.70%
Qiagen 4.68%14.61%8.80%

Alvotech currently has a consensus target price of $18.00, indicating a potential upside of 104.31%. Qiagen has a consensus target price of $49.40, indicating a potential upside of 3.26%. Given Alvotech's stronger consensus rating and higher probable upside, research analysts clearly believe Alvotech is more favorable than Qiagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Qiagen
0 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.30

70.0% of Qiagen shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alvotech has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

In the previous week, Alvotech had 1 more articles in the media than Qiagen. MarketBeat recorded 6 mentions for Alvotech and 5 mentions for Qiagen. Alvotech's average media sentiment score of 0.97 beat Qiagen's score of 0.50 indicating that Alvotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alvotech
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Qiagen
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Qiagen beats Alvotech on 9 of the 16 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALVO vs. The Competition

MetricAlvotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.66B$2.88B$5.46B$8.92B
Dividend YieldN/A2.44%5.24%4.04%
P/E Ratio23.8120.8027.0120.12
Price / Sales5.40193.35380.1493.35
Price / CashN/A41.7026.2128.59
Price / Book-6.437.487.995.57
Net Income-$231.86M-$55.04M$3.16B$248.40M
7 Day Performance-2.87%5.44%3.69%6.04%
1 Month Performance-17.35%2.38%2.91%7.69%
1 Year Performance-27.49%5.53%34.30%20.97%

Alvotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALVO
Alvotech
4.0052 of 5 stars
$8.81
-2.3%
$18.00
+104.3%
-25.6%$2.66B$491.98M23.811,032
QGEN
Qiagen
3.8725 of 5 stars
$48.07
+0.6%
$49.40
+2.8%
+18.8%$10.62B$1.98B120.525,765Dividend Announcement
VTRS
Viatris
2.676 of 5 stars
$8.93
-0.9%
$10.40
+16.5%
-10.9%$10.57B$14.74B-2.8232,000
ASND
Ascendis Pharma A/S
3.6058 of 5 stars
$172.60
+0.2%
$220.67
+27.8%
+29.6%$10.53B$393.54M-27.481,017Positive News
MRNA
Moderna
4.3806 of 5 stars
$27.59
+1.6%
$46.61
+68.9%
-74.7%$10.50B$3.24B-3.165,800
BBIO
BridgeBio Pharma
4.6714 of 5 stars
$43.18
-3.7%
$58.85
+36.3%
+68.9%$8.52B$221.90M-12.23400High Trading Volume
BPMC
Blueprint Medicines
1.516 of 5 stars
$128.18
+0.1%
$128.06
-0.1%
+15.0%$8.27B$508.82M-51.89640
VRNA
Verona Pharma PLC American Depositary Share
2.6162 of 5 stars
$94.58
+0.8%
$101.10
+6.9%
+466.1%$7.99B$42.28M-47.2930Positive News
ROIV
Roivant Sciences
1.5227 of 5 stars
$11.27
-1.1%
$17.50
+55.3%
+0.8%$7.74B$29.05M-45.08860
ELAN
Elanco Animal Health
2.3542 of 5 stars
$14.29
flat
$15.17
+6.1%
+1.8%$7.10B$4.44B19.319,000Analyst Upgrade
RVMD
Revolution Medicines
4.5679 of 5 stars
$36.79
-0.3%
$67.58
+83.7%
-2.3%$6.88B$11.58M-9.20250Positive News

Related Companies and Tools


This page (NASDAQ:ALVO) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners